Abbott Laboratories gained U.S. clearance Monday for a pair of new CGMs. The news could push Abbott stock closer to a breakout.
Amid a lack of Wall Street dealmaking this year, ETF issuers have been busy crafting new strategies. Our data show that 2024 paces to be a banner year for new US ETFs. Option ETFs, leveraged single-stock funds, and crypto are all big themes – with a newcomer set to grab the headlines.